GW Pharmaceuticals to Present at the 2020 Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference

Rhea-AI Summary

GW Pharmaceuticals announced its participation in the Needham Virtual Epilepsy & Pain Conference on December 10, 2020, at 11:00 AM EST. The presentation will focus on their advancements in cannabinoid prescription medicines.

A live audio webcast can be accessed via GW's corporate website. The company is known for its EPIDIOLEX product, which treats seizures linked to conditions like Lennox-Gastaut syndrome and Dravet syndrome in patients aged one and older.

LONDON and CARLSBAD, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference on Thursday, December 10, 2020 at 11:00am EST.

A live audio webcast of the presentation will be available through GW’s corporate website at www.gwpharm.com in the Investors section under Events & Presentations. A replay will be available soon after the live presentation.

About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, EPIDIOLEX^® (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX^® for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia. For further information, please visit www.gwpharm.com.

Enquiries:

GW Pharmaceuticals plc
Scott Giacobello, Chief Financial Officer	760 795 2200

FAQ

When will GW Pharmaceuticals present at the Needham Conference?

GW Pharmaceuticals will present at the Needham Virtual Epilepsy & Pain Conference on December 10, 2020, at 11:00 AM EST.

How can I watch GW Pharmaceuticals' presentation?

You can watch GW Pharmaceuticals' presentation live through their corporate website, under the Investors section.

What is EPIDIOLEX by GW Pharmaceuticals?

EPIDIOLEX is a cannabinoid oral solution used to treat seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients one year and older.

Is EPIDIOLEX available in Europe?

Yes, EPIDIOLEX is available in the EU under the name EPIDYOLEX, approved for treating seizures linked to Lennox-Gastaut and Dravet syndromes.

What additional products is GW Pharmaceuticals developing?

GW Pharmaceuticals is developing multiple cannabinoid products, including nabiximols, aimed at treating spasticity linked to multiple sclerosis and spinal cord injuries.